Consistency between direct and indirect trial evidence: Is direct evidence always more reliable?

Value in Health

Volumn 14, Issue 6, 2011, Pages 953-960

  Madan, Jason ^a   Stevenson, Matt D ^a   Cooper, Katy L ^a   Ades, A E ^a   Whyte, Sophie ^a   Akehurst, Ron ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Bayesian methods; febrile neutropenia; granulocyte colonystimulating factors; methodology; mixed treatment comparison

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

DIRECT TRIAL EVIDENCE; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FEBRILE NEUTROPENIA; HUMAN; INDIRECT TRIAL EVIDENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 80052708232     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.05.042     Document Type: Article

References (53)

1. L. Gleser, and I. Olkin Meta-analysis for 2X2 tables with multiple treatment groups D.K. Stangl, D.A. Berry, Meta-analysis in Medicine and Health Policy 2000 Marcel Dekker New York
2. J.P.T. Higgins, and J. Whitehead Borrowing strength from external trials in a meta-analysis Stat Med 15 1996 2733 2749 (Pubitemid 27011054)
3. V. Hasselblad Meta-analysis of multi-treatment studies Med Decis Making 18 1998 37 43
4. D.M. Caldwell, A.E. Ades, and J.P. Higgins Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 331 2005 89700
5. G. Lu, and A. Ades Assessing evidence consistency in mixed treatment comparisons JASA 101 2006 447 459 (Pubitemid 43972289)
6. National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf 2008 [Accessed May 23, 2011]
7. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] 2008 The Cochrane Collaboration, Wiley Chichester
8. F. Song, D. Altman, M.-A. Glenny, and J. Deeks Validity of indirect comparison for estimating efficacy of competing interventions: evidence from published meta-analyses BMJ 326 2003 472 476
9. R. Chou, F. Rongwei, L. Hoyt Huffman, and P.T. Korthuis Initial highly-active antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses Lancet 368 2006 1503 1515 (Pubitemid 44634694)
10. D.M. Caldwell, D.M. Gibb, and A.E. Ades Validity of indirect comparisons in meta-analysis Lancet 369 2007 270 (Pubitemid 46136478)
11. R. Chou, and R.W. Fu Validity of indirect comparisons in meta-analysis: authors' reply Lancet 369 2007 271 (Pubitemid 46138120)
12. G. Lu, and A.E. Ades Modelling between-trial variance structure in mixed treatment comparisons Biostatistics 10 2009 792 805
13. S. Dias, N.J. Welton, D.M. Caldwell, and A.E. Ades Checking consistency in mixed treatment comparison meta-analysis Stat Med 29 2010 932 944
14. W. DuMouchel Hierarchical Bayes Linear Models for Meta-analysis (Report No. 27) 1994 National Institute of Statistical Sciences Research Triangle Park, NC
15. E.C. Marshall, and D.J. Spiegelhalter Approximate cross-validatory predictive checks in disease mapping models Stat Med 22 2003 1649 1660 (Pubitemid 36575606)
16. D.J. Spiegelhalter, A. Thomas, N. Best, and D. Lunn WinBUGS User Manual: Version 1.4 2001 MRC Biostatistics Unit Cambridge, UK
17. N. Kuderer, D. Dale, J. Crawford, and G. Lyman Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 2007 3158 3167 (Pubitemid 47218066)
18. L. Pinto, Z. Liu, and Q. Doan Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials Curr Med Res Opin 23 2007 2283 2295 (Pubitemid 350246613)
19. C. Vogel, M. Wojtukiewicz, and R. Carroll First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 2005 1178 1184 (Pubitemid 46202274)
20. Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for prevention of febrile neutropenia following chemotherapy: systematic review and meta-analysis. University of Sheffield HEDS Discusssion Paper Series 2009;(09/07).
21. L. Balducci, H. Al-Halawani, and V. Charu Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim Oncologist 12 2007 1416 1424
22. G. Romieu, M. Clemens, and R. Mahlberg Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial Crit Rev Oncol Hematol 64 2007 64 72 (Pubitemid 47371205)
23. J.R. Hecht, M. Pillai, and R. Gollard Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): long-term results from a phase II, randomized, controlled study J Clin Oncol 27 Suppl. 2009 Abstract 4072
24. A. del Giglio, A. Eniu, and D. Ganea-Motan XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy BMC Cancer 8 2008 332
25. R. DerSimonian, and N. Laird Meta-analysis of clinical trials Control Clin Trial 7 1996 177 188
26. D.J. Spiegelhalter, N.G. Best, B.P. Carlin, and A. van der Linde Bayesian measures of model complexity and fit J R Stat Soc B 64 2002 583 616
27. National Institute for healthClinical Excellence Guide to the methods of technology appraisal 2008 NICE London
28. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The Results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691 (Pubitemid 27341818)
29. A.E. Ades, G. Lu, and J.P.T. Higgins The interpretation of random effects meta-analysis in decision models Med Decis Making 25 2005 646 654 (Pubitemid 41667133)
30. J.P.T. Higgins, S.G. Thompson, and D.J. Spiegelhalter A re-evaluation of random-effects meta-analysis J R Stat Soc A 172 2009 137 159
31. D.M. Caldwell, D.M. Gibb, and A.E. Ades Validity of indirect comparisons in meta-analysis Lancet 369 2007 270 (Pubitemid 46136478)
32. F. Song, I. Harvey, and R. Lilford Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions J Clin Epidemiol 61 2008 455 463 (Pubitemid 351446184)
33. G. Salanti, S. Dias, and N.J. Welton Evaluating novel agent effects in multiple treatments meta-regression Stat Med 29 2010 2369 2383
34. S. Dias, N.J. Welton, and V.C.C. Marinho Estimation and adjustment of bias in randomised evidence by using mixed treatment comparison meta-analysis J R Stat Soc A 173 2010 613 629
35. S.G. Moreno, A.J. Sutton, and E.H. Turner Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications BMJ 339 2009 b2981
36. J.K. Doorduijn, H.B. van der, and G.W. van Imhoff CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma J Clin Oncol 21 2003 3041 3050 (Pubitemid 46606283)
37. E. Osby, H. Hagberg, and S. Kvaloy CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial Blood 101 2003 3840 3848 (Pubitemid 36857855)
38. P.L. Zinzani, E. Pavone, and S. Storti Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma Blood 89 1997 3974 3979 (Pubitemid 27220941)
39. R. Pettengell, H. Gurney, J. Radford, and D. Deakin Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial Blood 80 1992 1430 1436
40. J. Timmer-Bonte, T. de Boo, and H. Smit Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study J Clin Oncol 23 2005 7974 7984 (Pubitemid 46657398)
41. V. Trillet-Lenoir, J. Green, and C. Manegold Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy Eur J Cancer 29 1993 319 324 (Pubitemid 23025731)
42. J. Crawford, H. Ozer, and R. Stoller Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325 1991 164 170
43. S.D. Fossa, S.B. Kaye, and G.M. Mead Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom J Clin Oncol 16 1998 716 724
44. B. Chevallier, P. Chollet, and Y. Merrouche Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer J Clin Oncol 13 1995 1564 1571
45. C. Gisselbrecht, C. Haioun, and E. Lepage Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration Groupe d'Etude des Lymphomes de l'Adulte Leuk Lymphoma 25 1997 289 300 (Pubitemid 27248180)
46. B.N. Bui, B. Chevallier, and C. Chevreau Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity J Clin Oncol 13 1995 2629 2636
47. V. Gebbia, R. Valenza, and A. Testa A prospective randomized trial of thymopentin versus granulocyte - colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy Anticancer Res 14 1994 731 734 (Pubitemid 24172200)
48. V. Gebbia, A. Testa, and R. Valenza A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma J Chemother 5 1993 186 190 (Pubitemid 23248932)
49. M. Green, H. Koelbl, and J. Baselga A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 2003 29 35 (Pubitemid 36150255)
50. F. Holmes, J. O'Shaughnessy, and S. Vukelja Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 2002 727 731 (Pubitemid 34111380)
51. F. Holmes, S. Jones, and J. O'Shaughnessy Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer Ann Oncol 13 2002 903 909 (Pubitemid 34752686)
52. J. Vose, M. Crump, and H. Lazarus Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma J Clin Oncol 21 2003 514 519 (Pubitemid 46606482)
53. A. Grigg, P. Solal-Celigny, and P. Hoskin Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma Leuk Lymphoma 44 2003 1503 1508 (Pubitemid 36833963)